Brooks Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Brooks Laboratories Ltd reported a 23.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 13.7%.
• Its expenses for the quarter were up by 22.3% QoQ and down 10.7% YoY.
• The net profit decreased 72.4% QoQ and decreased 204.1% YoY.
• The earnings per share (EPS) of Brooks Laboratories Ltd stood at 0.52 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Brooks Laboratories Ltd is a company engaged in the pharmaceutical industry, primarily focusing on the manufacturing and development of pharmaceutical products. The company is known for its emphasis on quality and innovation in the healthcare sector. While specific recent major developments are not provided in the data, Brooks Laboratories typically engages in activities that enhance its product portfolio and expand its market reach. As a participant in the pharmaceutical industry, the company is subject to regulatory approvals and the dynamic changes within the healthcare sector.

Revenue

In the fourth quarter of the fiscal year 2026, Brooks Laboratories Ltd reported a total income of ₹20.65 crores. This marks an increase of 23.7% compared to the previous quarter's total income of ₹16.69 crores. However, when compared to the same quarter in the previous fiscal year, Q4FY25, which recorded a total income of ₹23.94 crores, there is a decrease of 13.7%. This fluctuation in revenue generation reflects a notable change in sales performance over the year. The company’s ability to generate income has varied when compared year-over-year, highlighting a decrease in revenue relative to the previous fiscal year.

Profitability

The Profit Before Tax (PBT) for Q4FY26 was ₹0.61 crores, demonstrating a substantial quarter-over-quarter growth of 103.3% from the previous quarter's PBT of ₹0.30 crores. However, this represents a significant year-over-year decline of 59.6% compared to the PBT of ₹1.51 crores reported in Q4FY25. Interestingly, the company reported a Profit After Tax (PAT) of ₹1.52 crores in Q4FY26, which contrasts sharply with the previous quarter's PAT of ₹5.50 crores and the negative PAT of ₹-1.46 crores in the same quarter last year. The earnings per share (EPS) for Q4FY26 stood at ₹0.52, reflecting a decrease both quarter-over-quarter and year-over-year, with a 72.2% decline from the previous quarter and a 196.3% decrease from the same quarter the preceding fiscal year.

Operating Metrics

Total expenses for the fourth quarter of FY26 were ₹20.03 crores, which represents a 22.3% increase from the previous quarter's expenses of ₹16.38 crores. When compared to Q4FY25, where expenses were ₹22.43 crores, there is a 10.7% decrease. This indicates a reduction in expenses year-over-year, despite an increase quarter-over-quarter. The tax expense for Q4FY26 was reported as ₹0.00 crores, a continuation from the previous quarter and a notable reduction from the tax of ₹0.18 crores in the same quarter last year. These figures reflect the company’s operational efficiency and cost management over the fiscal periods examined.